Researchers have recently discovered that people who face a binge-eating disorder can follow treatment with Vyvanse to help with their condition. Vyavanse is a drug usually prescribed to people who suffer from attention-deficit/hyperactivity disorder (ADHD).
BED, the abbreviated binge-eating disorder, is a condition characteristic to people who consume massive amounts of food over a short period of time, in a fashion which jeopardizes one’s health. This behavior is in most cases kept hidden from family or friends, making it hard to spot and diagnose at an early stage.
People challenged with binge-eating have this behavior as frequently as once a week, lasting over a period of a few months. Binge-eating is not commonly linked to other unhealthy demeanors such as fasting, purging or excessive physical activity.
The most commonly methods to treat people suffering from binge-eating are psychotherapy and cognitive behavioral therapy. As it is known to happen, people who face this problem usually become very upset by their behavior, are depressed, have trouble sleeping and are extremely stressed. The National Institute of Diabetes and Digestive and Kidney Diseases informs that on a physical level, binge-eating can cause weight gain and health problems that may be related to that, such as diabetes or various heart conditions.
Recently a study has shown good result in treating binge-eating with Lisdexamfetamine dimesylate, the active ingredient in Vyvanse, a ADHD drug.
A clinical trial conducted by Susan McElroy from the Lindner Center of HOPE Mental Health and Addiction Center subjected 514 people suffering from binge-eating to a treatment with lisdexamfetamine. A third of the group was administered the drug at normal doses, a third at very low doses and the rest was administered a placebo.
The medical team found out that days when the binge-eating occurred were reduced significantly by the drug, compared to the group which was given a placebo. People who were given treatment with a low dose of the drug did not see improvement with their condition.
In September 2014, the Food and Drug Administration accepted a review of lisdexamfetamine, which is said to be completed in February of the current year. Although lisdexamfetamine is a schedule two drug – it cannot be prescribed to people with alcohol of drug problems -, this means that Vyvanse could become the first FDA-approved drug for the treatment of binge-eating disorder.
Image Source: Homefront United Network